TLD (Tenofovir + Lamivudine + Dolutegravir)
is a fixed-dose combination of Tenofovir disoproxil fumarate (300 mg), Lamivudine (300 mg), and Dolutegravir (50 mg) in a single tablet. It is the first-line recommended HIV treatment in Nigeria and worldwide, known for its high effectiveness, safety, and convenience (once-daily dosing).
Uses
First-line treatment of HIV-1 infection in adults and adolescents.
Helps suppress viral load to undetectable levels.
Improves immune function (increases CD4 count).
Reduces the risk of HIV-related illnesses and transmission.
Dosage
1 tablet once daily (with or without food).
Must be taken at the same time every day.
Treatment is lifelong and should never be stopped without medical advice.
Side Effects
Generally well tolerated.
Possible mild effects: headache, insomnia, dizziness, nausea, or diarrhea.
Rare but serious: kidney or liver issues, weight gain, or hypersensitivity reaction.
Precautions
Not recommended for patients with severe kidney disease unless adjusted by a doctor.
Inform your doctor if pregnant, breastfeeding, or taking other medications.
Must always be used under medical supervision.
